Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Orifarm Generics AB
AB
Active
Org 5566228937
Klara Södra Kyrkogata 1, 111 52
Stockholm
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 2002 · 24 years old
10-19 employees
Monitor
Share
Sweden
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Orifarm Generics AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
889M
667M
445M
222M
0M
2020: 332M
332M
2020
2021: 495M (+49% vs 2020)
495M
+49%
2021
2022: 488M (-1% vs 2021)
488M
-1%
2022
2023: 579M (+19% vs 2022)
579M
+19%
2023
2024: 714M (+23% vs 2023)
714M
+23%
2024
EBITDA
SEK millions
17M
13M
9M
4M
0M
2020: 3M
3M
2020
2021: 12M (+300% vs 2020)
12M
+300%
2021
2022: 9M (-25% vs 2021)
9M
-25%
2022
2023: 10M (+11% vs 2022)
10M
+11%
2023
2024: 14M (+40% vs 2023)
14M
+40%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
714 283
579 343
487 758
495 016
332 397
Staff expenses
—
—
—
—
—
EBITDA
14 286
10 139
8 536
12 330
2 987
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
14 286
10 139
8 536
12 330
2 987
Net financials
708
1 157
4 166
−681
−1 279
Profit before tax
15 013
11 330
12 755
11 884
2 121
Tax
−2 685
−2 758
−2 691
−2 459
−460
Net profit
12 328
8 572
10 064
9 425
1 661
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
129 478
150 322
110 637
79 919
45 898
Equity
31 906
30 779
28 906
18 843
9 418
Long-term debt
0
0
0
0
0
Short-term debt
97 572
119 543
81 731
61 076
36 480
Total debt
97 572
119 543
81 731
61 076
36 480
Financial ratios
5-year trend
EBITDA margin
2,0 %
This company
15,8 %
Market median
This company
Market median
87% below market
2020
2024
Equity ratio
24,6 %
This company
38,2 %
Market median
This company
Market median
36% below market
2020
2024
Return on equity
38,6 %
This company
18,4 %
Market median
This company
Market median
110% above market
2020
2024
Net profit margin
1,7 %
This company
8,1 %
Market median
This company
Market median
79% below market
2020
2024
Asset turnover
5,52×
This company
1,12×
Market median
This company
Market median
393% above market
2020
2024
Debt / equity
3,06×
This company
0,62×
Market median
This company
Market median
394% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Orifarm Generics AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
